5 completed. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 1 | Completed 1 |
Follow Nova Pneuma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Staccato® Granisetron Single Dose PK 0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010 - Healthy | Phase 1 | Completed | Nova Pneuma Inc. | 36 | 2019-11-04 | 2026-04-13 |
| Staccato Alprazolam and Photoparoxysmal Response A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m - Epilepsy | Phase 2 | Completed | Nova Pneuma Inc. | 5 | 2015-01-01 | 2026-04-20 |
| Staccato Loxapine Thorough QT/QTc Study Inhaled loxapine, Inhaled placebo, Oral moxifloxacin - Thorough QT/QTc Study | Phase 1 | Completed | Nova Pneuma Inc. | 48 | 2009-04-01 | 2026-04-22 |
| Staccato Alprazolam Abuse Liability Inhaled placebo + oral placebo, Inhaled alprazolam 0.5 mg, Inhaled alprazolam 1 mg - Abuse Liability of Staccato Alprazolam | Phase 1 | Completed | Nova Pneuma Inc. | 31 | 2008-01-01 | 2026-04-22 |
| Staccato Prochlorperazine Single Dose PK Study Prochlorperazine 0.5 mg IV over 5 sec, Inhaled prochlorperazine 0.625 mg, Inhaled prochlorperazine 1.25 mg - Migraine | Phase 1 | Completed | Nova Pneuma Inc. | 54 | 2004-08-01 | 2026-04-22 |
Epilepsy (1) · Migraine Disorders (1)
Alprazolam (1) · Equipment and Supplies (1) · Granisetron (1) · Loxapine (1) · Moxifloxacin (1) · Prochlorperazine (1) · Solutions (1)
United States (5)
Daniel A Spyker, MD (1) · J Isojarvi, MD (1) · Phillip Mathew, MD (1) · Randall R. Stoltz, MD (1) · Roland R Griffiths, PhD (1)